Please correct me if I’m wrong. laurus in entering into innovator molecule cdmo in agrochem and animal Pharma. These aren’t generic molecules. Hence margin might be lower as compared to human Pharma cdmo, but will be higher than generic formulation and APIs.
Also asset turns would be higher as compared to human Pharma. Hence it will not dilute the Roce imo.
| Subscribe To Our Free Newsletter |
